News ⁽⁴⁾

Cambridge Nucleomics is delighted to announce the appointment of Dr Anthony (Tony) Cooke as Independent chairman of the board. Dr Cooke brings over 40 years' in vitro diagnostic (IVD) development and commercialisation experience to the company. His extensive career spans the entire product lifecycle, from…

Cambridge Nucleomics has successfully closed an oversubscribed £550 k pre-seed round led by Cambridge Angels with participation from Cambridge Technology Capital. In a strong vote of confidence toward Nucleomics' founding team and revolutionary modular soluble nanoarray (MSN) technology platform, this capital injection will directly fund…

Cambridge Nucleomics is proud to be awarded the 2025 Trinity Bradfield Angel Prize jointly with BioTryp Therapeutics in recognition of achievements over the past 12 months. The prize was evaluated and awarded by a distinguished panel of scientific experts, industry leaders and VCs led by…

Cambridge Nucleomics is honoured to have won the prestigious 2024 Trinity Bradfield Prize. Awarded by Nobel laureate and serial entrepreneur Sir Greg Winter, this prize provided crucial early-stage validation for our vision to break the diagnostic bottleneck in molecular testing. Over the past six months,…